Last reviewed · How we verify
Febuxostat 80 MG
At a glance
| Generic name | Febuxostat 80 MG |
|---|---|
| Also known as | Feburic 80, Andouristat 80 mg, Staturic 80 mg |
| Sponsor | Ain Shams University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Immediate Prescription of a Hypouricemic Treatment, Febuxostat, Compared to Its Delayed Administration (PHASE3)
- Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostat on Gouty Obese Non-Diabetic Patients (PHASE2)
- Comparative Study Between Febuxostat Versus Vitamin E in Non-alcoholic Steatohepatitis Patients With Hyperuricemia (PHASE2)
- Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion (PHASE4)
- Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets (PHASE1)
- A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients (PHASE3)
- The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF) (PHASE4)
- A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Febuxostat 80 MG CI brief — competitive landscape report
- Febuxostat 80 MG updates RSS · CI watch RSS
- Ain Shams University portfolio CI